Ischemic Stroke Clinical Trial
Official title:
Walkbot Robotic Training for Improvement in Gait in Sub-Acute Stroke
This clinical study will involve up to 30 ischemic stroke inpatients during their stay at Burke Rehabilitation Hospital. Participants will be randomized to receive 30 additional minutes of therapy every day, for a total of 2 weeks (14 days). One group will receive 30 minutes of standard physical therapy focused on pre-gait or gait training activities, while the experimental group will receive 30 minutes of Walkbot with Augmented Reality. Both groups will receive the same time in therapy aimed at gait training.
This controlled clinical study will involve 30 ischemic stroke inpatients during their stay
at Burke Rehabilitation Hospital (typical inpatient arrives 7 days post-stroke and is
admitted for ~16 days).
Stroke inpatients will be sequentially randomized into one of two groups within the first
week after admission. Both Groups will receive 30 additional minutes of therapy every day,
for a total of 2 weeks (14 days). Group A will enroll 15 patients who will receive usual
inpatient care including at least one 60-minute session of physical therapy per day, and an
additional 30-minute session of standard physical therapy focused on pre-gait and/or gait
training activities 5-days per week during the duration of their stay (14 days). Group B will
enroll 15 patients who receive usual inpatient care that includes at least one 60-minute
session of physical therapy and an additional 30-minute session of Walkbot with Augmented
Reality 5-days per week during the duration of their stay (14 days). Both groups will receive
the same time in therapy aimed at gait training. The extra therapy group will not exceed more
than 15 minutes of pregait training before starting to walk the patient, and will spend at
least 15 minutes doing active gait training per session. Patients in the treatment group will
receive 30 minutes of total training on the Walkbot, excluding setup time. Primary and
secondary outcomes will be collected, prior to the first therapy session. Follow up outcome
measures will be collected within two days after the final interventional (study) therapy
session. The amount of therapists needed for each session will be logged for every patient
after Walkbot training or extra physical therapy. Borg rating of perceived exertion will be
taken after each session from the patients, and NASA Task Load Index will be completed by the
therapists (ie therapist load). Outcomes will be analyzed for significant differences.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Completed |
NCT03281590 -
Stroke and Cerebrovascular Diseases Registry
|
||
Recruiting |
NCT05518305 -
Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis
|
||
Recruiting |
NCT06029959 -
Stroke and CPAP Outcome Study 3
|
N/A | |
Recruiting |
NCT03728738 -
Zero Degree Head Positioning in Hyperacute Large Artery Ischemic Stroke
|
Phase 3 | |
Terminated |
NCT03396419 -
IMPACT- 24col Collateral Blood Flow Assessment Following SPG Stimulation in Acute Ischemic Stroke (ImpACT-24B Sub-Study)
|
||
Recruiting |
NCT05065216 -
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
|
Phase 2/Phase 3 | |
Recruiting |
NCT04897334 -
Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke
|
N/A | |
Not yet recruiting |
NCT06462599 -
Osteopontin Gene Polymorphism in Stroke Patients in Egypt
|
||
Not yet recruiting |
NCT06026696 -
Cohort of Neurovascular Diseases Treated in the Acute Phase and Followed at Lariboisière
|
||
Not yet recruiting |
NCT06032819 -
Differentiating Between Brain Hemorrhage and Contrast
|
||
Recruiting |
NCT02910180 -
Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders
|
||
Completed |
NCT02922452 -
A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects
|
Phase 1 | |
Withdrawn |
NCT01866189 -
Identification of Hypoxic Brain Tissues by F-MISO PET in Acute Ischemic Stroke
|
N/A | |
Recruiting |
NCT03041753 -
Reperfusion Injury After Stroke Study
|
N/A | |
Completed |
NCT02549846 -
AdminiStration of Statin On Acute Ischemic stRoke patienT Trial
|
Phase 4 | |
Completed |
NCT02610803 -
Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke
|
N/A | |
Completed |
NCT01678534 -
Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial
|
Phase 2 | |
Terminated |
NCT01852201 -
POSITIVE Stroke Clinical Trial
|
N/A |